Clinical Trials Browser

Phase 1/2 × Leukemia, Myeloid, Acute × tislelizumab × Clear all

NCT06586099 2024-09-19

Tislelizumab with Azacitidine in the Treatment of R/R AML

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute